Select the elements you want to hide on this page.
Save
Cancel
Press Releases
Press Releases
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets